Tyra Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep '24 Sep 30, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
Net Income	-83.74	-69.13	-55.33	-26.29	-9.34	-4.07
Depreciation & Amortization	0.47	0.35	0.3	0.14	0.05	0.01
Loss (Gain) From Sale of Assets	0	0	0	0	0	-
Loss (Gain) From Sale of Investments	-5.95	-1.25	-	-	-	-
Stock-Based Compensation	20.29	13.53	10.59	2.89	0.44	-
Other Operating Activities	-	-	-	-	0.02	0.93
Change in Accounts Payable	2.12	9.37	2.36	1.49	1.02	0.46
Change in Other Net Operating Assets	3.09	-3.01	-8.2	-1.97	0.05	0.04
Operating Cash Flow	-63.72	-50.14	-50.29	-23.75	-7.76	-2.62
Capital Expenditures	-1.26	-0.77	-0.56	-0.66	-0.31	-0.02
Sale of Property, Plant & Equipment	-	-	-	0.02	-	-
Investment in Securities	-248.54	-143.84	-	-	-	-
Investing Cash Flow	-249.8	-144.61	-0.56	-0.65	-0.31	-0.02
Long-Term Debt Repaid	-	-	-	-0.01	-0.02	-0.01
Net Debt Issued (Repaid)	-	-	-	-0.01	-0.02	-0.01
Issuance of Common Stock	202.18	1.54	0.63	181.73	0.14	0.17
Financing Cash Flow	201.76	1.54	0.63	311.35	23.43	0.16
Net Cash Flow	-111.76	-193.21	-50.21	286.96	15.36	-2.48
Free Cash Flow	-64.98	-50.91	-50.84	-24.41	-8.08	-2.64
Free Cash Flow Per Share	-1.22	-1.19	-1.21	-1.77	-5.24	-1.00
Cash Interest Paid	-	-	-	1.24	0	0
Levered Free Cash Flow	-37.57	-29.49	-28.56	-14.18	-8.98	-
Unlevered Free Cash Flow	-37.57	-29.49	-28.56	-14.18	-8.97	-
Change in Net Working Capital	-5.47	-7.37	2.05	0.12	3.34	-

Source: S&P Capital IQ. Standard template. Financial Sources.